Drug Price Trends for NDC 59011-0415

Average Pharmacy Cost for 59011-0415

Drug Name	NDC	Price/Unit ($)	Unit	Date
OXYCONTIN ER 15 MG TABLET	59011-0415-10	8.66487	EACH	2026-01-01
OXYCONTIN ER 15 MG TABLET	59011-0415-20	8.66487	EACH	2026-01-01
OXYCONTIN ER 15 MG TABLET	59011-0415-10	7.98613	EACH	2025-12-17
OXYCONTIN ER 15 MG TABLET	59011-0415-20	7.98613	EACH	2025-12-17
OXYCONTIN ER 15 MG TABLET	59011-0415-20	7.98664	EACH	2025-11-19
OXYCONTIN ER 15 MG TABLET	59011-0415-10	7.98664	EACH	2025-11-19

Best Wholesale Price for NDC 59011-0415

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
OXYCONTIN 15MG CONTROLLED-RELEASE TAB	Purdue Pharma L.P.	59011-0415-10	100	478.51	4.78510	2023-01-01 - 2027-04-30	FSS
OXYCONTIN 15MG CONTROLLED-RELEASE TAB	Purdue Pharma L.P.	59011-0415-10	100	501.62	5.01620	2023-03-15 - 2027-04-30	Big4
OXYCONTIN 15MG CONTROLLED-RELEASE TAB	Purdue Pharma L.P.	59011-0415-10	100	502.44	5.02440	2023-03-15 - 2027-04-30	FSS
OXYCONTIN 15MG CONTROLLED-RELEASE TAB	Purdue Pharma L.P.	59011-0415-10	100	518.66	5.18660	2024-01-01 - 2027-04-30	Big4
OXYCONTIN 15MG CONTROLLED-RELEASE TAB	Purdue Pharma L.P.	59011-0415-10	100	527.57	5.27570	2024-01-01 - 2027-04-30	FSS
OXYCONTIN 15MG TAB	Purdue Pharma L.P.	59011-0415-20	20	86.13	4.30650	2022-05-01 - 2027-04-30	Big4

Novo Nordisk Ozempic (Semaglutide) Market Analysis and Price Projections

Last updated: February 17, 2026

Ozempic, marketed by Novo Nordisk, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes. Its efficacy in glycemic control and significant weight loss potential has driven substantial market growth. This analysis examines current market dynamics and projects future pricing for Ozempic.

What is the Current Market Size and Growth Trajectory for Ozempic?

The global market for Ozempic is experiencing rapid expansion, driven by increasing diabetes prevalence and the drug's demonstrated benefits beyond glycemic control. In 2023, the Ozempic market size was estimated at approximately $15 billion. Projections indicate sustained double-digit compound annual growth rate (CAGR) through 2030, with some analysts forecasting the market to exceed $30 billion by that year. This growth is attributable to several factors:

• Increasing Diabetes Prevalence: The International Diabetes Federation (IDF) reported that 537 million adults worldwide lived with diabetes in 2021, a number projected to rise to 783 million by 2045 [1]. Ozempic addresses a significant unmet need within this growing patient population.
• Cardiovascular Benefits: Clinical trial data, such as the SUSTAIN-6 trial, have demonstrated Ozempic's ability to reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease [2]. This expanded indication and demonstrated outcome benefit enhance its market position.
• Weight Management Potential: Beyond its primary indication, Ozempic has shown significant efficacy in promoting weight loss, leading to off-label use and increased demand. Novo Nordisk's development of semaglutide for obesity (Wegovy) further validates this aspect of the drug's utility and contributes to the overall semaglutide franchise growth.
• Geographic Expansion: Novo Nordisk has been actively seeking and obtaining regulatory approvals for Ozempic in numerous countries, broadening its global market reach. Key markets include the United States, Europe, and increasingly, emerging economies in Asia-Pacific and Latin America.

The competitive landscape for GLP-1 receptor agonists is intensifying. Eli Lilly's tirzepatide (Mounjaro/Zepbound) has emerged as a significant competitor, demonstrating comparable or superior efficacy in clinical trials for both glycemic control and weight loss. However, Ozempic benefits from a well-established safety profile and brand recognition built over several years.

What are the Key Drivers and Restraints for Ozempic Market Growth?

Drivers:

• Evolving Treatment Paradigms: The shift towards combination therapies and outcome-focused treatment strategies in diabetes management favors drugs like Ozempic that offer multiple benefits, including glycemic control, weight reduction, and cardiovascular risk mitigation.
• Increasing Physician and Patient Awareness: Extensive clinical trial data and direct-to-consumer marketing campaigns have increased awareness of Ozempic's efficacy and benefits among both healthcare providers and patients.
• Launch of New Formulations and Dosing: While Ozempic is currently available as a once-weekly injection, potential future developments in formulations or delivery methods could further enhance patient adherence and market penetration.
• Growing Obesity Epidemic: The global rise in obesity rates, coupled with Ozempic's demonstrated weight loss effects, is driving demand, although this is largely met by the dedicated obesity indication of Wegovy. The overlap in patient profiles and shared manufacturing resources between Ozempic and Wegovy create a synergistic growth dynamic for Novo Nordisk.

Restraints:

• High Cost and Reimbursement Challenges: The significant price of Ozempic can be a barrier to access, particularly in markets with limited insurance coverage or high out-of-pocket costs for patients. Reimbursement policies vary significantly by country and payer, impacting market penetration.
• Adverse Event Profile: While generally well-tolerated, Ozempic can cause gastrointestinal side effects such as nausea, vomiting, and diarrhea. These side effects can lead to treatment discontinuation for some patients. The risk of pancreatitis and thyroid C-cell tumors (observed in rodent studies, relevance in humans uncertain) are also noted concerns.
• Competition from Other Drug Classes: The diabetes market features a diverse range of therapeutic options, including DPP-4 inhibitors, SGLT2 inhibitors, and insulin therapies. The development of novel oral GLP-1 receptor agonists and other innovative treatments also presents ongoing competitive pressure.
• Supply Chain Constraints: Due to exceptionally high demand, Ozempic has experienced intermittent supply shortages globally. Novo Nordisk has invested in expanding manufacturing capacity, but these constraints have limited sales growth at times and created opportunities for competitors.

What is the Current Pricing Landscape for Ozempic?

The pricing of Ozempic varies by country due to differing regulatory environments, market dynamics, and reimbursement policies. However, a general overview of the pricing structure can be established:

• United States: The list price for a 4-week supply (four 0.25 mg, 0.5 mg, or 1 mg pens; or two 2 mg pens) of Ozempic typically ranges from $900 to $1,000 USD. This list price is often subject to significant discounts and rebates negotiated by pharmacy benefit managers (PBMs) and insurance providers.
• Europe: Prices in European countries are generally lower than in the US, influenced by national health service price negotiations and reference pricing mechanisms. For example, in the United Kingdom, the NHS price for a 4-week supply might be in the range of £100 to £150 GBP (approximately $125 to $190 USD), depending on the dose and specific formulary agreements. In Germany, prices for similar quantities could be around €100 to €130 EUR ($110 to $140 USD).
• Canada: Prices for Ozempic in Canada typically fall between $250 to $350 CAD per 4-week supply.
• Australia: The Pharmaceutical Benefits Scheme (PBS) subsidizes Ozempic, resulting in a co-payment for eligible patients. The general patient co-payment for a 4-week supply is typically around $40 AUD, with concession card holders paying less.

Table 1: Estimated Ozempic Pricing (Per 4-Week Supply)

Region	Dose Range	Estimated Price Range (USD)
United States	0.25 mg to 2 mg pens	$900 - $1,000
United Kingdom	0.25 mg to 2 mg pens	$125 - $190
Germany	0.25 mg to 2 mg pens	$110 - $140
Canada	0.25 mg to 2 mg pens	$220 - $310
Australia	0.25 mg to 2 mg pens (co-pay)	$25 - $35

Note: Prices are estimates and subject to change. USD equivalents for non-USD currencies are based on current exchange rates and may fluctuate.

The pricing strategy for Ozempic is influenced by its premium positioning as a highly effective GLP-1 receptor agonist with significant benefits. Novo Nordisk also employs tiered pricing strategies based on dose strength and duration of treatment. The wholesale acquisition cost (WAC) remains high, with actual net prices for payers being lower due to rebates and volume discounts.

What are the Projections for Ozempic's Future Pricing?

Forecasting the future pricing of Ozempic involves considering several dynamic factors:

• Patent Expiry and Generic Competition: The primary patent for semaglutide is expected to expire in the United States in 2031 and in Europe around the same timeframe, though specific market-by-market patent cliffs will vary. The introduction of generic semaglutide would significantly impact pricing, potentially leading to a 30-50% reduction in average selling prices within a few years of generic entry.
• Continued Demand and Supply Dynamics: While demand is expected to remain robust, especially with expanded indications and patient access, ongoing investments in manufacturing capacity by Novo Nordisk may alleviate current supply constraints. However, persistent high demand relative to production could support price stability or modest increases in the short to medium term.
• Competitive Market Entry: The approval and market penetration of competing GLP-1 RAs and other novel diabetes and weight-loss medications will exert downward pressure on Ozempic's price. Companies like Eli Lilly with tirzepatide are already challenging Ozempic's market share.
• Payer Negotiations and Value-Based Pricing: Payers are increasingly scrutinizing the cost-effectiveness of high-priced drugs. Negotiations for reimbursement will continue to be critical. The demonstration of long-term outcome benefits, such as cardiovascular event reduction, may allow for premium pricing to be maintained longer, but this is contingent on robust real-world evidence and formulary inclusion.
• Inflationary Pressures and Manufacturing Costs: General inflation and increases in the cost of raw materials, manufacturing, and distribution will exert upward pressure on prices. Novo Nordisk will likely adjust prices to reflect these operational cost increases.

Projected Pricing Trend:

• Short-Term (1-3 years): Prices are likely to remain relatively stable or see modest increases of 1-3% annually, driven by sustained demand, inflationary pressures, and continued R&D investment by Novo Nordisk. Price increases will be tempered by payer pushback and the growing competitive landscape.
• Medium-Term (4-7 years): As patent expiry approaches and competition intensifies, some price erosion may begin, particularly in markets with established pathways for biosimilar/generic entry. However, for innovator products like Ozempic, significant price reductions are unlikely until actual generic competition emerges. Prices may stabilize or experience marginal declines of 1-2% annually in certain regions due to competitive pressures.
• Long-Term (8+ years): Following patent expiry, substantial price decreases are anticipated, potentially in the range of 40-60%, as generic versions enter the market. The speed and magnitude of this decline will depend on the number of generic manufacturers, their production capacities, and the regulatory approval timelines for generics.

Table 2: Ozempic Price Projection Scenarios

Time Horizon	Scenario	Expected Annual Price Change	Primary Influencing Factors
1-3 Years	Stable to Modest Increase	+1% to +3%	High demand, inflationary costs, limited generic competition
4-7 Years	Stabilization/Slight Decline	-1% to +1%	Increasing competition, approaching patent cliff, payer scrutiny
8+ Years (Post-Patent)	Significant Decrease	-40% to -60% (cumulative)	Generic/biosimilar market entry, increased supply, price competition

What are the Intellectual Property Considerations for Ozempic?

Novo Nordisk holds a robust portfolio of patents protecting Ozempic (semaglutide). The core patent covering the semaglutide molecule is expected to expire in the US in 2031. However, the company also holds patents related to:

• Formulations: Various inventive formulations of semaglutide, including those designed for improved stability, delivery, or patient convenience, may have different expiry dates.
• Manufacturing Processes: Patents covering specific synthesis routes or purification methods for semaglutide could extend market exclusivity for certain aspects of its production.
• Methods of Treatment: New indications or specific treatment regimens discovered for semaglutide may be protected by separate patents, potentially extending market exclusivity for those specific uses.
• Delivery Devices: Patents for the injection pens and other delivery devices used with Ozempic also contribute to its overall market protection.

Navigating the intellectual property landscape is crucial for understanding the true duration of Ozempic's market exclusivity. While the primary compound patent is a key determinant, the interplay of secondary patents can create complex legal challenges for potential generic manufacturers. Novo Nordisk actively defends its intellectual property through litigation and by securing new patents for incremental innovations.

Key Takeaways

Ozempic is a leading GLP-1 receptor agonist with significant market traction driven by its efficacy in type 2 diabetes and weight management, as well as cardiovascular benefits. The current market size is substantial, with projected strong growth. Pricing is high, particularly in the US, but subject to significant payer negotiations. Future pricing will be shaped by patent expiry in 2031, intensifying competition, and continued demand. Post-patent expiry, a substantial price decrease is expected due to generic entry.

FAQs

1. When is the primary Ozempic patent expected to expire, and what is the typical impact on drug pricing after patent expiry? The primary patent for semaglutide is expected to expire in the United States in 2031. Following patent expiry, the introduction of generic versions typically leads to significant price reductions, often in the range of 40% to 60% within a few years as market competition intensifies.

2. What are the main factors influencing the current price variations of Ozempic across different countries? Price variations are influenced by national healthcare systems, regulatory approval processes, reimbursement policies, local market dynamics, and the level of competition within each country. Countries with national health services or price negotiation frameworks often have lower prices than those with more market-driven pricing.

3. Besides the primary compound patent, what other types of intellectual property protect Ozempic and could affect its market exclusivity? Novo Nordisk also holds patents on semaglutide formulations, specific manufacturing processes, new methods of treatment for identified indications, and the drug delivery devices. These secondary patents can extend market exclusivity for certain aspects of the product or its specific uses even after the primary compound patent expires.

4. How does the competition from other GLP-1 receptor agonists, such as tirzepatide, impact Ozempic's pricing strategy? The emergence of highly effective competitors like tirzepatide exerts downward pressure on Ozempic's pricing. Novo Nordisk must balance maintaining premium pricing based on established benefits with the need to remain competitive in a dynamic market, potentially leading to more aggressive rebate strategies or price adjustments in certain segments.

5. What is the anticipated effect of Ozempic's demonstrated weight loss efficacy on its market value and pricing, independent of its primary diabetes indication? The significant weight loss potential, while contributing to off-label use and driving demand, is more directly addressed by Novo Nordisk's dedicated obesity medication, Wegovy (also semaglutide). However, the overall success and market validation of semaglutide for weight management enhance the franchise value, indirectly supporting the pricing power of Ozempic by demonstrating broad therapeutic utility and driving demand within the broader metabolic health space.

Citations

[1] International Diabetes Federation. (2021). IDF Diabetes Atlas (10th ed.). Retrieved from https://www.diabetesatlas.org/

[2] Green, J. B., Mudaliar, S., Rav B. P., Marso, S. P., et al. (2017). Efficacy and Safety of Once-Weekly Semaglutide in Adults with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. The Lancet, 389(10072), 927-937. https://doi.org/10.1016/S0140-6736(17)30383-0